Pharmacogenomics: Reflecting on the old and new social, ethical and policy issues in postgenomics medicine

Advances in Biological Psychiatry

Volumn 25, Issue , 2010, Pages 12-29

  Ozdemir, Vural ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870271557     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000317296     Document Type: Article

References (57)

1. Bertilsson L, Palmér L: Indole-3-acetic acid in human cerebrospinal fluid: Identification and quantification by mass fragmentography. Science 1972; 177: 74-76.
2. Eichelbaum M, Bertilsson L: Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. J Chromatogr 1975; 103: 135-140.
3. Gram LF, Christiansen J: First-pass metabolism of imipramine in man. Clin Pharmacol Ther 1975; 17: 555-563.
4. De Leon J: Pharmacogenomics: The promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34: 159-172.
5. Human Genome Project: Ethical, Legal and Social Issues. www.ornl.gov/sci/techresources/Human- Genome/elsi/elsi.shtml (accessed November 9, 2009).
6. Collins FS, Green ED, Guttmacher AE, Guyer MS; US National Human Genome Research Institute: A vision for the future of genomics research. Nature 2003; 422: 835-847.
7. ELSA, European Commission: Ethical, Legal and Social Aspects of the Life Science and the Technologies. http://cordis.europa.eu/elsa-fp4/home.html (accessed November 9, 2009).
8. Hedgecoe AM: Critical bioethics: Beyond the social science critique of applied ethics. Bioethics 2004; 18: 120-143.
9. Illinois White Paper: Improving the System for Protecting Human Subjects: Counteracting IRB 'Mission Creep'. Center for Advanced Study, University of Illinois. 2005.
10. Guston DH: Innovation policy: Not just a jumbo shrimp. Nature 2008; 454: 940-941.
11. Ozdemir V, Suarez-Kurtz G, Stenne R, Somogyi A, Someya T, Kayaalp SO, Kolker E: Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of 'edge effect' and cultivating an ethical bridge between omics innovations and society. OMICS 2009; 13: 43-62.
12. Ozdemir V: What to do when the risk environment is rapidly shifting and heterogeneous? Anticipatory governance and real time assessment of social risks in multiply marginalized populations can prevent ethical inflation or underestimation of risks. Am J Bioethics 2009; 9: 65-68.
13. Egalité N, Ozdemir V, Godard B: Pharmacogenomics research involving racial classification: qualitative research findings on researchers' views, perceptions and attitudes towards socioethical responsibilities. Pharmacogenomics 2007; 8: 1115-1126.
14. World Health Organization: Genomics and World Health. Geneva, WHO, 2002. www.who.int/rpc/genomics-report.pdf (accessed November 9, 2009).
15. Pharmacogenetics: Ethical Issues. London, Nuffield Council on Bioethics, 2003.
16. Advisory Committee on Genetics, Health, and Society: Realizing the Potential of Pharmacogenomics: Opportunities and Challenges; A Report of the Secretary's Advisory Committee on Genetics, Health, and Society. Health and Human Services, 2008, p 24. http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS-PGx- report.pdf.
17. House of Lords Science and Technology Committee: 2nd Report of Session 2008-09. Genomic Medicine Volume I. London, Authority of the House of Lords, 2009.
18. Nuremberg Code: Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law. Washington, US Government Printing Office, 1949, pp 181-182.
19. Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (DHEW Publication No. (OS) 78-0012). National Commission for the Protection of Human Subjects in Biomedical and Behavioral Research . 1978.
20. Beauchamp TL, Childress JF: Principles of Biomedical Ethics, ed 6. Oxford, Oxford University Press, 2008.
21. Fox RC: More than bioethics. Hastings Cent Rep 1996; 26: 5-7.
22. Fox RC, Swazey JP: Examining American bioethics: Its problems and prospects. Camb Q Health Ethics 2005; 14: 361-373.
23. Guessous I, Gwinn M, Yu W, Yeh J, Clyne M, Khoury MJ: Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics 2009; 12: 142-148.
24. Ozdemir V, Someya T: A transdisciplinary forum for study of individual and population variability in response to health interventions and personalized medicine (editorial). Curr Pharmacogenomics Person Med 2009; 7: 146-148.
25. Corrigan O: Empty ethics: The problem with informed consent. Sociol Health Illn 2003; 25: 768-792.
26. Burton B: Proposed genetic database on Tongans opposed. BMJ 2002; 324: 443.
27. Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, Lewis G, Detmar S, van den Akker-van Marle ME, Hedgecoe AM, Nightingale P, Dreiling M, Hartig KJ, Vullings W, Forde T: Putting pharmacogenetics into practice. Nat Biotechnol 2006; 24: 403-410.
28. UK Pharmacogenetics Study Group: Policy Issues in Pharmacogenetics: A Policy Briefing from the UK Pharmacogenetics Study Group. 2006. www. york.ac.uk/res/pgx/publications/PGxpolicyissues2006. pdf (accessed November 9, 2009).
29. Pang T: Pharmacogenomics and personalized medicine for the developing world - too soon or just-intime? A personal view from the World Health Organization. Curr Pharmacogenomics Person Med 2009; 7: 149-157.
30. Prainsack B, Reardon J, Hindmarsh R, Gottweis H, Naue U, Lunshof JE: Personal genomes: Misdirected precaution. Nature 2008; 456: 34-35.
31. Corrigan OP: Pharmacogenetics, ethical issues: Review of the Nuffield Council on Bioethics Report. J Med Ethics 2005; 31: 144-148.
32. Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, Cohen N, Edeki T, Franc M, Hillgren KM, Johnson KJ, Katz DA, Milton MN, Murray BP, Polli JW, Ricci D, Shipley LA, Vangala S, Wrighton SA: PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 2008; 48: 849-889.
33. McGuire AL, Hamilton JA, Lunstroth R, Mc-Cullough LB, Goldman A: DNA data sharing: Research participants' perspectives. Genet Med 2008; 10: 46-53.
34. Genetic Information Nondiscrimination Act of 2008, Pub. L. 110-233, 122 Stat. 881, 2008.
35. Korobkin R, Rajkumar R: The Genetic Information Nondiscrimination Act - A half-step toward risk sharing. N Engl J Med 2008; 359: 335-337.
36. Lunshof JE: From genetic privacy to open consent. Person Med 2006; 3: 187-194.
37. Machanavajjhala A, Kifer D, Gehrke J, Venkitasubramaniam M: L -diversity: Privacy beyond k -anonymity. ACM Trans Knowl Discov 2007; 1:article 3.
38. Lee SS, Mudaliar A: Medicine. Racing forward: The Genomics and Personalized Medicine Act. Science 2009; 323: 342.
39. Bloche MG: Race-based therapeutics. N Engl J Med 2004; 351: 2035-2037.
40. Kahn J: Exploiting race in drug development: BiDil's interim model of pharmacogenomics. Soc Stud Sci 2008; 38: 737-758.
41. US Office of Management and Budget: Standards for Maintaining, Collecting, and Presenting Federal Data on Race and Ethnicity. 1997. www.whitehouse. gov/omb/inforeg/r&e-app-a-update.pdf (accessed November 9, 2009).
42. Lee SS: The ethical implications of stratifying by race in pharmacogenomics. Clin Pharmacol Ther 2007; 81: 122-125.
43. Suarez-Kurtz G: Pharmacogenomics and the genetic diversity of the Brazilian population. Cad Saude Publica 2009; 25: 1650-1651.
44. Yen-Revollo JL, Auman JT, McLeod HL: Race does not explain genetic heterogeneity in pharmacogenomic pathways. Pharmacogenomics 2008; 9: 1639-1645.
45. Montoya MJ: Bioethnic conscription: Genes, race, and mexicana/o ethnicity in diabetes research. Cult Anthropol 2007; 22: 94-128.
46. Ellison GTH, Smart A, Tutton R, Outram SM, Ashcroft R, Martin P: Racial categories in medicine: A failure of evidence-based practice? PLoS Med 2007; 4: 1434-1436.
47. Hahn R, Mulinare J, Teutsch S: Inconsistencies in coding race and ethnicity between birth and death in US infants. JAMA 1992; 267: 259-263.
48. Leech K: Runnymede Research Report. London, Runnymede Trust, 1989. A Question in Dispute: The Debate About an 'Ethnic' Question in the Census.
49. Lowe A, Urquhart A, Foreman L, Evett I: Inferring ethnic origin by means of an STR profile. Forensic Sci Int 2001; 119: 17-22.
50. Medicines in Development for Major Diseases Affecting African Americans. Washington, Pharmaceutical Research and Manufacturers Association of America, 2007.
51. Moncrieff J, Thomas P: The pharmaceutical industry and disease mongering: Psychiatry should not accept so much commercial sponsorship. BMJ 2002; 325: 216.
52. Paik YK, Graham JE, Jones M, McDonald F, Holmes C, Ozdemir V: Interview with Dr. Young-Ki Paik, President of the Human Proteome Organization (HUPO): Pharmacoproteomics and the approaching wave of 'proteomics diagnostics'. Curr Pharmacogenomics Person Med 2009; 7: 243-248.
53. Veblen T: The Instinct of Workmanship and the State of the Industrial Arts. New York, Macmillian, 1914.
54. Ozdemir V, Husereau D, Hyland S, Samper S, Salleh MZ: Personalized medicine beyond genomics: New technologies, global health diplomacy and anticipatory governance. Curr Pharmacogenomics Person Med 2009;7:225-230.
55. Knoppers BM: Genomics and policy-making: From static models to complex systems? Hum Genet 2009;125:375-379.
56. Kato K, Kano K, Shirai T: Science communication: Significance for genome-based personalized medicine - A view from the Asia-Pacific. Curr Pharmacogenomics Person Med 2010;8:92-96.
57. Ozdemir V, Knoppers BM: One size does not fit all: Towards 'upstream ethics'? Am J Bioethics 2010; 10:42-44.